• 1
    Davis R, Peters DH, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332372.
  • 2
    Licht RW. Drug treatment of mania: a critical review. Acta Psychiatry Scand 1998;97:387397.
  • 3
    Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103108.
  • 4
    Isojärvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579584.
  • 5
    Isojärvi JI, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446451.
  • 6
    Isojärvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:13831388.
  • 7
    Luef GJ, Waldmann M, Sturm W, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol 2004;55:729732.
  • 8
    Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:6569.
  • 9
    Panksepp J, Meeker RB. The role of GABA in the ventromedial hypothalamic regulation of food intake. Brain Res Bull 1980;5(suppl 2):453460.
  • 10
    Ponchaut S, Veitch K. Valproate and mitochondria. Biochem Pharmacol 1993;46:199204.
  • 11
    Vorum H, Gram L, Honoré B. Valproate and palmitate binding to serum albumin in valproate treated patients: relation to obesity. Epilepsy Res 1993;16:5564.
  • 12
    Luef GJ, Lechleitner M, Bauer G, et al. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55:5358.
  • 13
    Pylvänen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003;60:571574.
  • 14
    Pyorala M, Miettinen H, Laakso M, et al. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998;29:18601866.
  • 15
    Zavaroni I, Bonini L, Fantuzzi M, et al. Hyperinsulinaemia, obesity, and syndrome X. J Intern Med 1994;235:5156.
  • 16
    Haffner SM, Ferrannini E, Hazuda HP, et al. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992;20:3845.
  • 17
    Isojarvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001;111:290296.
  • 18
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489501.
  • 19
    Ranua J, Luoma K, Peltola J, et al. Anticardiolipin and antinuclear antibodies in epilepsy: a population-based cross-sectional study. Epilepsy Res 2004;58:1318.
  • 20
    Luef G, Abraham I, Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:12741278.
  • 21
    Nakae J, Accili D. The mechanism of insulin action [Review]. J Pediatr Endocrinol Metab 1999;12(suppl 3):721731.
  • 22
    Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473481.
  • 23
    Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666670.
  • 24
    Luef G, Abraham I, Trinka E, et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 2002;48:91102.
  • 25
    Horwitz DL, Starr JI, Mako ME, et al. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 1975;55:12781283.
  • 26
    Granner DK. Hormones of the pancreas. In: MurrayRK, ed. Harpers biochemistry. Norwalk , Calif: Prentice-Hall, International Editions, 1988;547563.
  • 27
    Steiner DF, Terris S, Chan SJ, et al. Chemical and biological aspects of insulin and proinsulin. Acta Med Scand 1976;(suppl 601):53107.
  • 28
    Mykkänen L, Haffner SM, Hales CN, et al. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 1997;46:19901995.
  • 29
    Johnston DG, Alberti KGMM., Faber OK, et al. Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion? Lancet 1977;1:1012.
  • 30
    Bonora E, Zavaroni I, Coscelli C, et al. Decreased hepatic insulin extraction in subjects with mild glucose intolerance. Metabolism 1983;32:438446.
  • 31
    Kissebah AH. Insulin resistance in visceral obesity. Int J Obes 1991;15(suppl 2):109115.
  • 32
    Pylvänen V, Knip M, Pakarinen A, et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514517.
  • 33
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412419.